1


Report to the
GAVI Alliance Board

Board -2011 -Mtg -2-Doc 07
7-8 July 2011
Subject : Accelerated Vaccine Introduction ? progress report
Report of: Nina Schwalbe, MD, Policy and Performance
Authored by: Jon Pearman, Director of Accelerated Vaccine
Introduction (AVI) Initiative
Agenda item : 07
Category: For Discussion
Strategic goal: SG1 - Vaccines and SG4 - Market shaping


Section A: Overview


1. Purpose of the report

1.1 To provide a summary on the progress of the Accelerated Vaccine Introduction
(AVI) initiative and to review ongoing challenges to building a successful
platform for future introduction of new vaccines.


2. Recommendations

2.1 The Board is recommended to take note of this report, in particular the
following:

(a) GAVI had an excellent start of its pneumococcal (pneumo) vaccine roll out
under AVI. Since manufacturers signed initial supply agreements under the
Advance Market Commitment (AMC) last year, pneumo vaccines have
been shipped to twelve countries on three continents. Vaccine supply is
tight but we are confident that we can meet the needs of 19 approved
countries. Beyond this, as anticipated, additional supply contracts are
needed.

(b) Rotavirus (rota) vaccine implementation outside of Latin America is
scheduled to start in 2011 and accelerate i n 2012.

(c) In May 2011, GAVI received a record number of 75 new applications for
new vaccines 1 from 50 countries.

1 Pneumo conjugate vaccine (PCV), rotavirus, meningitis A, yellow fever (YF), Haemophilus influenzae type B
vaccine (HiB) and measles 2nd dose vaccines.

Board -2011 -Mtg -2-Doc 00b




GAVI Alliance Board Meeting
7-8 July 2011
Intercontinental Hotel, Geneva, Switzerland

Wednesday, 6 July: Pre -Board m eetings
Thursday , 7 July: 8.30 -18.30 (Board meeting Day One)
Friday , 8 July: 8.00 -15.15 (Board meeting Day Two)
Quorum: 12

Agenda (v. 30 June 2011)

Pre -Board Meetings ? Wednesday 6 July 2011
Item Subject Room Schedule

Preview of the new GAVI Alliance website ?
available all day

Foyer 9.00 -18.00
A Pre -Board meetings ? Morning session
? Technical briefing on cash based programmes
? IFFIm Board meeting
? AMC stakeholders meeting
? Civil society organisations meeting
? Chair?s individual meetings with Committee Chairs


Ballroom C
Berne
Ballroom B
Ballroom C
10.00 -13.30
10.00 -11.00
11.00 -12.30
11.15 -13.30
11.30 -13.00
Ongoing
Lunch

Benelux -Lon dres 12.30 -14.30
B Pre -Board meetings ? Afternoon session
? IFFIm donors meeting
? Developing country Board members meeting
? GAVI donors meeting
? New Board members meeting hosted by the Chair
? Unaffiliated board members briefing


Ballroom C
Berne
Ballroom B
Ballroom C
Berne
13.30 -17.30
13.30 -15.30
14.00 -16.00
15.30 -17. 30
16.00 -17.00
16. 15 -17.00
C Governance Committee meeting

Berne

17. 30-19.00
D GAVI Alliance Board ? Closed session
? Dinner
? Follow up to Oslo retreat

Ballrooms A -E

19.00-21. 30

Next Board Meeting : 16 -17 November 2011, Dhaka, Bangladesh ---
Debbie Adams , Secretary, +41 22 909 6504, dadams@gavialliance.org
Kevin A. Klock , Assistant Secretary, +1 202 478 7734, kklock@gavialliance.org

GAVI Alliance Board Meeting, 30 November ? 1 December 2010 Doc # 11e ? AVI Progress Report

FOR INFORMATION

GAVI Secretariat, 16 November 2010 1

This paper provides an update on the Accelerated Vaccine Introduction
initiative (AVI). It is for information only. A more detailed progress report
was presented to the Programme and Policy Committee in September) and
can be provided to Board members upon request.

Accelerated Vaccine Introduction (AVI) Progress Report

Background
1. The aim of GAVI?s Accelerated Introduction Initiative ( AVI) is to drive the
sustainable introduction of rotavirus vaccine and pneumococcal conjugate
vaccine in GAVI -eligible countries. Initial targets for th e initiative, set in 2008,
were to launch rotavirus vaccines in 44 countries and pneumococcal
conjugate vaccines in 42 countries by 2015. The targets are now revised to
align with the GAVI Alliance strategy 2011- 2105.

2. The AVI is coordinated by an interagency team (?AVI management team?)
consist ing of representatives of WHO, UNICEF, AVI Technical Assistance
Consortium (AVI TAC
1

) and the GAVI Secretariat. It is led by the GAVI
Secretariat and the Bill & Melinda Gates Fou ndation participate as an
observer. The management team has established a number of dedicated
sub -teams for key work areas including: strategic vaccine supply, large
countries, cold chain and logistics, and ad- hoc pneumococcal vaccine
introduction.
3. The A VI management team provides detailed reports to the Programme and
Policy Committee in addition a half day briefing session is scheduled prior to
each PPC meeting and AVI is standing item on the PPC agenda.

Progress since June
4. Following the Executive Com mittee approval of paused applications in August
2010, there are now 19 countries approved for pneumo introduction and one
country approved for rota introduction. Introduction is being planned for
pneumo in 13 countries over the next 12 months, and, in tot al, in 19 countries
over the next 24 months. For rota, introduction is being planned for 1 country
over the next 12 months.
5. The AVI management team and sub- team members ha ve been involved in
the development of the GAVI Strategy and Business Plan , including
1 A consortium of PATH, Johns Hopkins University (JHU), US Centers for Disease Control and Prevention (CDC)
and others

GAVI Alliance Board Meeting, 30 November - 1 December 2010 Doc #07 c ? GAVI Alliance
Business Plan 2011 -2015
Annex 2- Strategic Goals and
Cross -cutting issues

GAVI Secretariat 16 November 2010 1

Annex 2 Business Plan Part II
Strategic Goals and C ross Cutting -Issues

Summary

Strategic goal 1: Accelerating the uptake of new and underused vaccines

Accelerating the uptake of new and underused vaccines (?the vaccine goal?) is
GAVI?s core business, and has been since it was founded. For this reason, it also
represents the majority of GAVI?s business plan budget.

The first ten years of GAVI?s work focused mostly on yellow fever, HepB and Hib
containing vaccines. In the second decade, GAVI aims to maintain momentum on
these antigens while accelerating introduction of routine meningitis, pneumococcal
and rotavirus vaccines and supporting campaigns against yellow fever and
meningitis. The Alliance will also begin acti vities to prepare for new and underused
vaccines, including HPV, Japanese Encephalitis, Typhoid, and Rubella. If the
Alliance is fully resourced to meet demand, up to 100 new vaccine introductions
across GAVI -eligible countries would occur between 2011 an d 2015. The majority of
these introductions are pneumococcal and rotavirus vaccines - 70 countries in the
strategy period ? 40 of which introduce between 2011 and 2012.

Countries take the decisions to introduce vaccines, and are responsible for
managing the introduction of the vaccine. The GAVI secretariat and the members of
the Alliance ? primarily the multilateral partners and the AVI technical assistance
consortium ? can draw upon their comparative advantages and resources to help
countries:

? Improv e decision -making on vaccines , by strengthening decision making
bodies, providing impact information about specific vaccine introduction,
development of policy standards and reporting systems and producing key
scientific data. and to monitor of the results ;

? Strengthen vaccine introduction, by supporting, primarily through technical
assistance and training, cold chain capacity, supply plan management,
programme administration, monitoring and reporting, waste disposal,
surveillance systems and advocacy and s ocial mobilisation.

The programme objectives and deliverables under the vaccine goal identify the key
activities which will support this, which agency is responsible, and what budget is
available.

Funding for partner agencies is requested in those area s where the Alliance
activities necessitate additional effort as a consequence of supporting activities
funded by GAVI:

? WHO: develops global policy on immunisation recommendations, standards,
global reporting on disease burden and immunisation programmes. Provides